[1]SHUCH B,AMIN A,ARMSTRONG AJ,et al.Understanding pathologic variants of renal cell carcinoma:distilling therapeutic opportunities from biologic complexity［J］.European Urology,2015,67(1):85-97.
[2]NICKERSON ML,JAEGER E,SHI Y,et al.Improved identification of von hippel-lindau gene alterations in clear cell renal tumors［J］.Clinical Cancer Research,2008,14(15):4726-4734.
[3]JANOWITZ T,WELSH SJ,ZAKI K,et al.Adjuvant therapy in renal cell carcinoma-past,present,and future［J］.Minnesota Oncology,2013,40(4):482-491.
[4]STEPHENSON AJ,CHETNER MP,ROURKE K,et al.Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy［J］.Journal of Urology,2004,172(1):58-62.
[5]CHOUEIRI TK,MOTZER RJ.Systemic therapy for metastatic renal cell carcinoma［J］.The New England Journal of Medicine,2017,376(4):354-366.
[6]CHOUEIRI TK,POWLES T,BUROTTO M,et al.Nivolumab plus Cabozantinib versus sunitinib for advanced renal-cell carcinoma［J］.The New England Journal of Medicine,2021,384(9):829-841.
[7]MOTZER RJ,JONASCH E,AGARWAL N,et al.Kidney cancer,version 3.2022,NCCN clinical practice guidelines in oncology［J］.Journal of the National Comprehensive Cancer Network,2022,20(1):71-90.
[8]IY SHENG,BI RINI.Immunotherapy for renal cell carcinoma［J］.Expert Opinion on Biological Therapy,2019,19(9):897-905.
[9]CHANG AJ,ZHAO L,ZHU Z,et al.The past,present and future of immunotherapy for metastatic renal cell carcinoma［J］.Anticancer Research,2019,39(6):2683-2687.
10]CHEN DS,MELLMAN I,et al.Oncology meets immunology:the cancer-immunity cycle［J］.Immunity,2013,25,39(1):1-10.
11]MOTZ,GT,COUKOS,G,et al.Deciphering and reversing tumor immune suppression［J］Immunity,2013,39(1):61-73.
12]VIGANO S,PERREAU M,PANTALEO G,et al.Positive and negative regulation of cellular immune responses in physiologic conditions and diseases［J］Clinical and Developmental Immunology,2012,2012:485781.
13]LIANG SC,LATCHMAN YE,BUHLMANN JE,et al.Regulation of PD-1,PD-L1,and PD-L2 expression during normal and autoimmune responses［J］.European Journal of Immunology,2003,33(10):2706-2716.
14]THOMPSON RH,GILLETT MD,CHEVILLE JC,et al.Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma［J］.Cancer,2005,104(10):2084-2091.
[15]RINI BI,PLIMACK ER,STUS V,et al.KEYNOTE-426 investigators.Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma［J］.The New England Journal of Medicine,2019,380(12):1116-1127.
[16]YAMAGUCHI H,HSU JM,YANG WH.Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics［J］.Nature Reviews Clinical Oncology,2022,19(5):287-305.
[17]CHOUEIRI TK,POWLES T,BUROTTO M,et al.CheckMate 9ER investigators.nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma［J］.The New England Journal of Medicine,2021,384(9):829-841.
[18]ROWSHANRAVAN B,HALLIDAY N,SANSOM DM.CTLA-4:a moving target in immunotherapy［J］.Blood,2018,131(1):58-67.
[19]BEDKE J,ALBIGES L,CAPITANIO U,et al.The 2021 updated european association of urology guidelines on renal cell carcinoma:immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care［J］.European Urology,2021,80(4):393-397.
[20]CHA JH,CHAN LC,LI CW,et al.Mechanisms controlling PD-L1 expression in cancer［J］.Molecular Cell,2019,76(3):359-370.
[21]ADACHI Y,KAMIYAMA H,ICHIKAWA KF,et al.Inhibition of FGFR reactivates IFNγ signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies［J］.Cancer Researcher,2022,82(2):292-306.
[22]GAO J,SHI LZ,ZHAO H,et al.Loss of IFN-g pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy［J］.Cell,2016,167(2):397-404.e9.
[23]BENCI JL,XU B,QIU Y,et al.Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade［J］.Cell,2016,167(6):1540-1554.e12.
[24]PAN Y,SHU G,FU L,et al.EHBP1L1 drives immune evasion in renal cell carcinoma through binding and stabilizing jak1［J］.Advanced Science,2023,10(11):e2206792.
[25]SIVAN A,CORRALES L,HUBERT N,et al.Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy［J］.Science,2015,350(6264):1084-1089.
[26]ROUTY B,LE CHATELIER E,DEROSA L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors［J］.Science,2018,359(6371):91-97.
[27]DIZMAN N,MEZA L,BERGEROT P,et al.Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma:a randomized phase 1 trial［J］.Nature Medicine,2022,28(4):704-712.
[28]LALANI AA,XIE W,BRAUN DA,et al.Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma［J］.European Urology Oncology,2020,3(3):372-381.
[29]ZHOU J,HUANG G,WONG WC,et al.The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors［J］.Frontiers in Immunology,2022,13:968729.
[30]BOI SK,ORLANDELLA RM,GIBSON JT,et al.Obesity diminishes response to PD-1-based immunotherapies in renal cancer［J］.Immunother Cancer,2020,8(2):e000725.
[31]CORTELLINI A,BERSANELLI M,SANTINI D,et al.Another side of the association between body mass index(BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1(PD-1)/Programmed cell death-ligand 1(PD-L1) checkpoint inhibitors:A multicentre analysis of immune-related adverse events［J］.European Journal of Cancer,2020,128:17-26.
[32]XIONG W,ZHANG B,YU H,et al.RRM2 regulates sensitivity to sunitinib and PD-1 blockade in renal cancer by stabilizing anxa1 and activating the akt pathway［J］.Advanced Science,2021,8(18):e2100881.
[33]HUDES G,CARDUCCI M,TOMCZAK P,et al.Temsirolimus,interferon alfa,or both for advanced renal-cell carcinoma［J］.The New England Journal of Medicine,2007,356(22):2271-2281.
[34]ZHANG C,DUAN Y,XIA M,et al.TFEB mediates immune evasion and resistance to mtor inhibition of renal cell carcinoma via induction of PD-L1［J］.Clinical Cancer Research,2019,25(22):6827-6838.
[35]WANG M,ZHAO J,ZHANG L,et al.Role of tumor microenvironment in tumorigenesis［J］.Cancer,2017,8(5):761-773.
[36]HANAHAN D,COUSSENS LM.Accessories to the crime:functions of cells recruited to the tumor microenvironment［J］.Cancer Cell,2012,21(3):309-322.
[37]QUAIL DF,JOYCE JA.Microenvironmental regulation of tumor progression and metastasis［J］.Nature Medicine,2013,19(11):1423-1437.
[38]CHEN S,CRABILL GA,PRITCHARD TS,et al.Mechanisms regulating PD-L1 expression on tumor and immune cells［J］.Immunother Cancer,2019,7(1):305.
[39]FONG L,HOTSON A,POWDERLY JD,et al.Adenosine 2A receptor blockade as an immunotherapy for treatment refractory renal cell cancer［J］.Cancer Discovery,2020,10(1):40-53.
[40]ALLARD B,POMMEY S,SMYTH MJ,et al.Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs［J］.Clinical Cancer Research,2013,19(20):5626-5635.
[41]HATFIELD SM.Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1alpha-dependent and extracellular adenosine-mediated tumor protection［J］.Journal of Molecular Medicine,2014,92(12):1283-1292.
[42]KUMAR V,GABRILOVICH DI.Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment［J］.Immunology,2014,143(4):512-519.
[43]BARSOUM IB,KOTI M,SIEMENS DR,et al.Mechanisms of hypoxia-mediated immune escape in cancer［J］.Cancer Research,2014,74(24):7185-7190.
[44]ERICSSON JL,SELJELID R,ORRENIUS S.Comparative light and electron microscopic observations of the cytoplasmic matrix in renal carcinomas［J］.Virchows Archiv,1966,341(3):204-223.
[45]NOTARANGELO G,SPINELLI JB,PEREZ EM,et al.Oncometabolite d-2HG alters T cell metabolism to impair CD8+T cell function［J］.Science,2022,377(6614):1519-1529.
[46]LIN H,FU L,LI P.Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma［J］.Journal of Translational Medicine,2023,21(1):343.
[47]LI L,ZENG X,CHAO Z,et al.Targeting alpha-ketoglutarate disruption overcomes immunoevasion and improves PD-1 blockade immunotherapy in renal cell carcinoma［J］.Advanced Science,2023,10(27):e2301975.
[48]SAITO Y,FUJIWARA Y,SHINCHI Y,et al.Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis［J］.Cancer Science,2022,113(9):3255-3266.
[49]CHEN S,CRABILL GA,PRITCHARD TS,et al.Mechanisms regulating PD-L1 expression on tumor and immune cells［J］.Immunother Cancer,2019,7(1):305.
[50]TAKAMATSU K,TANAKA N,HAKOZAKI K,et al.Profiling the inhibitory receptors LAG-3,TIM-3,and TIGIT in renal cell carcinoma reveals malignancy［J］.Nature Communications,2021 20,12(1):5547.
[51]KOYAMA S,AKBAY EA,LI YY.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints［J］.Nature Communications,Research,2016,7:10501.
[52]ZELBA H,BEDKE J,HENNENLOTTER J.PD-1 and LAG-3 dominate checkpoint receptor-mediated T-cell inhibition in renal cell carcinoma［J］.Cancer Immunol Research,2019,7(11):1891-1899.
[53]HU J,CHEN Z,BAO L,et al.Single-cell transcriptome analysis reveals intratumoral heterogeneity in ccRcc,which results in different clinical outcomes［J］.Molecular Therapy,2020,28(7):1658-1672.
[54]SAITO Y,FUJIWARA Y,SHINCHI Y,et al.Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis［J］.Cancer Science,2022,113(9):3255-3266.
[55]GARON EB,RIZVI NA,HUI R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer［J］.The New England Journal of Medicine,2015,372(21):2018-2028.
[56]ZHANG X,YIN X,ZHANG H.Differential expressions of PD-1,PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma［J］.BMC Cancer,2019,19(1):360.
[57]ECKEL-PASSOW JE,HO TH,SERIE DJ.Concordance of PD-1 and PD-L1(B7-H1) in paired primary and metastatic clear cell renal cell carcinoma［J］.Cancer Medicine,2020,9(3):1152-1160.
[58]ATKINS MB,JEGEDE OA,HAAS NB.Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma(HCRN GU16-260-Cohort B)［J］.Clinical Oncology,2022,40(25):2913-2923.
[59]MOHAMAD O,DIAZ DE LEON A,SCHROEDER S,et al.Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy［J］.Oncoimmunology,2018,7(7):e1440168.
[60]YANG WS,SRIRAMARATNAM R,WELSCH ME,et al.Regulation of ferroptotic cancer cell death by GPX4［J］.Cell,2014,156(1-2):317-331.
[61]MARKOWITSCH SD,SCHUPP P,LAUCKNER J,et al.Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis［J］.Cancers,2020,12(11):3150.
[62]YI M,ZHENG X,NIU M,et al.Combination strategies with PD-1/PD-L1 blockade:current advances and future directions［J］.Molecular Cancer Research,2022,21(1):28.